The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Efficacy of VenDd vs DVd in patients with t(11;14) R/R myeloma
In this video, Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, briefly highlights some preliminary findings from a Phase I study on patients with relapsed multiple myeloma. Following this, Dr Kaufman gives a detailed update on results from a 3-part Phase I/II randomized continuation of this study (NCT03314181). In his discussion, Dr Kaufman compares the use of two doses of venetoclax, daratumumab and dexamethasone (VenDd) versus a combination of bortezomib, daratumumab and dexamethasone (DVd) in patients with t(11;14) positive relapsed and/or refractory (R/R) myeloma. Dr Kaufman explains the benefits observed, including overall response rate and infection rate, providing context from a safety and efficacy perspective. Dr Kaufman also mentions the potential use of this data for a future Phase III trial. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
